Luteal estradiol administration strengthens the relationship between day 3 follicle-stimulating hormone and inhibin B levels and ovarian follicular status

Fertil Steril. 2003 Mar;79(3):585-9. doi: 10.1016/s0015-0282(02)04757-x.

Abstract

Objective: To investigate whether the prevention of early follicular growth by luteal E(2) administration improves the relationship between day 3 hormone measurements and the ovarian follicular status.

Design: Prospective, cohort study.

Setting: Assisted reproductive technology unit in Clamart, France.

Patient(s): One hundred sixty-two infertile women.

Intervention(s): Participants received oral 17beta-E(2), 4 mg/day, from day 20 to the next cycle day 1 (n = 81) or served as controls (n = 81). Serum E(2), inhibin B, and FSH were measured during the 3 days after E(2) discontinuation (FD1, FD2, and FD3) in E(2)-treated women and on cycle day 3 (CD3) in controls. Early antral follicles were counted at ultrasound scans on FD3 and CD3.

Main outcome measure(s): Hormonal-follicular correlations on FD3 and CD3.

Result(s): As expected, after E(2) withdrawal, inhibin B and FSH increased from FD1 to FD3 whereas E(2) decreased. Correlations between FSH and inhibin B and follicular counts were stronger on FD3 than on CD3.

Conclusion(s): Luteal E(2) administration notably strengthens the relationship between serum FSH and inhibin B levels and the number of antral follicles on day 3. This approach may represent an alternative test of ovarian follicular status.

MeSH terms

  • Adult
  • Cohort Studies
  • Estradiol / administration & dosage*
  • Estradiol / blood
  • Female
  • Follicle Stimulating Hormone / blood*
  • Humans
  • Inhibins / blood*
  • Luteal Phase*
  • Ovarian Follicle / physiology*
  • Prospective Studies

Substances

  • inhibin B
  • Estradiol
  • Inhibins
  • Follicle Stimulating Hormone